• United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercise and share sales on Aug. 3, 2026.
• A family trust acquired 9,500 common shares via option exercise at USD 135.42.
• The trust sold 9,500 common shares at weighted-average prices ranging from USD 514.83 to USD 518.61.
• Trust-held common shares fell to 324,443 following the transactions.
• Trust-held stock options totaled 217,910 after the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000112), on August 04, 2026, and is solely responsible for the information contained therein.